Inclusion Criteria:  DNA damage response (DDR) mutations documented in the past medical record or confirmed during the screening period. Measurable disease defined by RECIST 1.1. Life expectancy ≥ 3 months. Subject must be capable of oral administration of study medication.  Exclusion Criteria:  Subject has had a cytotoxic chemotherapy, immunotherapy, radiotherapy or other targeted therapies within 4 weeks. Surgical procedure performed within 7 days prior to first scheduled dose of ATRN-119. Concomitant treatment with strong inhibitors or inducers of CYP3A4 and CYP2D6. Known human immunodeficiency virus infection (HIV). Subjects with active viral or bacterial infections and/or receiving systemic antibiotics or anti-viral medications. Current or past diagnosis of leukemia within the past 5 years. Prior radiotherapy at the target lesion unless there is evidence of disease progression. Known CNS metastases or clinical evidence of CNS involvement that is not stable for previous 1 month by radiology documentation (magnetic resonance imaging [MRI] brain). History of non-malignant gastronintestinal (GI) bleeding, gastric stress ulcerations, or peptic ulcer disease within the past 3-months. Patient has uncontrolled hypertension at time of enrollment. Complete left bundle branch block (LBBB), bifascicular block (right bundle branch block [RBBB] with either left anterior hemiblock or left posterior hemiblock). Any clinically significant ST segment and/or T-wave abnormalities. Myocardial infarction or unstable angina pectoris within 6 months prior to starting study medication.